MEN1 and pancreatic insulinoma: Cre targeting of MEN1 in pancreatic progenitor cells using a Pdx1-Cre recombinase demonstrated endocrine only pancreatic insulinoma development at 10–12 months, resulting from increased VEGF expression, which could be reduced by anti-VEGF therapy [141].